Drug Trial Radar · NCT06953726
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Oct 4, 2032
Study completion Oct 3, 2033
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Food and Drug Administration (FDA)
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure. * The trial only enrolls patients with a diagnosis of atrial fibrillation ("A Fib") or atrial flutter. Most participants will be age 65 or older, and should already be taking apixaban or rivaroxaban. * The investigators will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs. * The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.
Conditions
- Atrial Fibrillation
Interventions
ApixabanDrug
Study participants will be randomized to twice daily oral administration of apixaban 5 milligrams (mg). Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years, body weight 60 kg, and serum creatinine 1.5 mg/dL.
RivaroxabanDrug
Study participants will be randomized to daily oral administration of rivaroxaban 20 milligrams (mg). Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL/min.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Onset of ISTH Major Bleeding EventTime frame: 3 years
- Time to First StrokeTime frame: 3 years
- Time to First Systemic EmbolismTime frame: 3 years
- Time to All-Cause MortalityTime frame: 3 years
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California · Active not recruiting
Miami VA Healthcare System, Miami, FL
Miami, Florida · Recruiting
Boston VA CSP Coordinating Center
Boston, Massachusetts · Recruiting
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts · Not yet recruiting
Minneapolis VA Call Center
Minneapolis, Minnesota · Recruiting
Louis Stokes VA Medical Center, Cleveland, OH
Cleveland, Ohio · Active not recruiting
VA Portland Health Care System, Portland, OR
Portland, Oregon · Recruiting
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania · Active not recruiting
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.